GSK's $10.6B acquisition of Nuvalent is a transformative oncology deal that accelerates entry into lung cancer with two late-stage assets under FDA review. The 40% premium and $9.4B net cash outlay are material but funded via debt/cash with no credit rating impact. Near-term EPS dilution through FY2028 is manageable; accretion begins in 2029. Key catalysts: FDA decisions on zidesamtinib (Sept 2026) and neladalkib (Nov 2026). Monitor tender offer close (expected Q3 2026) and any competing bids for Nuvalent. For GSK holders, the deal strengthens long-term growth but adds execution risk in oncology.
Price Chart
Executive Summary
GSK plc announced a definitive agreement to acquire Nuvalent, Inc. for $10.6 billion ($124/share in cash), a 40% premium to last close. The deal adds two late-stage, potential best-in-class ROS1/ALK inhibitors (zidesamtinib, neladalkib) for NSCLC, with FDA PDUFA dates in Sept/Nov 2026, plus a phase I HER2 inhibitor and preclinical pipeline. GSK reaffirmed its 2026 guidance of 7-9% core operating profit and EPS growth, expects low single-digit EPS dilution through FY2028, and accretion to core EPS by 2029.
Key Facts
- GSK to acquire Nuvalent for $10.6 billion aggregate equity value ($124/share cash), representing a 40% premium to last closing price and 26% premium to 30-day VWAP.
- Net of cash acquired, GSK's investment is estimated at $9.4 billion (£7.1 billion).
- Acquisition includes two late-stage assets: zidesamtinib (ROS1 inhibitor, PDUFA 18 Sept 2026) and neladalkib (ALK inhibitor, PDUFA 27 Nov 2026), both with FDA Breakthrough Therapy and Orphan Drug Designations.
- GSK reaffirms FY2026 guidance of 7-9% core operating profit and core EPS growth; expects low single-digit EPS dilution in FY2026, FY2027, and FY2028.
- Transaction expected to be accretive to sales and core operating profit in 2027, and core EPS in 2029, inclusive of synergies and reprioritisation.
- Funding primarily from new and existing debt plus cash; no impact expected to GSK's credit rating; 70p dividend for 2026 reaffirmed.
- GSK will assume low-single-digit royalties payable to Royalty Pharma and Deerfield from Nuvalent's existing arrangements.
Financial Impact
$10.6 billion aggregate equity value; $9.4 billion net of cash acquired; 40% premium to last close; low single-digit EPS dilution through FY2028; accretion to core EPS by 2029.
Risk Factors
- FDA non-approval or delayed approval of zidesamtinib or neladalkib would materially impair deal value.
- Low single-digit EPS dilution through FY2028 could pressure near-term earnings.
- Integration and commercial execution risks in a competitive NSCLC market.
- Potential competing bids for Nuvalent or antitrust hurdles under HSR Act.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005800 |
| Document: 0001654954-26-005800-index-headers.html | 0001654954-26-005800 |
| Document: 0001654954-26-005800-index.html | 0001654954-26-005800 |
| Document: 0001654954-26-005800.txt | 0001654954-26-005800 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 19w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 19w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers